1059630-11-3

Basic information

• Product Name: 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1)
• Synonyms: 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1);6-Bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride;6-bromo-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;EOS-62293
• CAS NO: 1059630-11-3
• Molecular Formula: C₁₁H₁₁BrN₂*ClH
• Molecular Weight: 287.58338
• Mol File: 1059630-11-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1)(1059630-11-3)
• EPA Substance Registry System: 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1)(1059630-11-3)

Safety Data

• Hazardous Substances Data: 1059630-11-3(Hazardous Substances Data)

Usage

General Description

1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1) is a chemical compound with the molecular formula C12H14BrN·HCl. It is a hydrochloride salt of the natural alkaloid 6-bromo-2,3,4,5-tetrahydro-1H-benzo[g]indole, which has been isolated from various plant sources. 1H-Pyrido[4,3-b]indole, 6-bromo-2,3,4,5-tetrahydro-, hydrochloride (1:1) is commonly used in pharmacological research as a tool compound to investigate its potential biological activities and interactions with other molecules. It also has potential therapeutic applications in the treatment of various diseases, although further research is necessary to fully understand its properties and mechanisms of action.

Upstream product

• 41979-39-9 4-piperidone hydrochloride 
• 50709-33-6 2-bromophenylhydrazine hydrochloride 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 

Downstream Products

• 1059630-12-4 racemate 6-bromo-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole 
• 313368-82-0 4-((6bR,10aS)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1576240-17-9 C₂₃H₂₆FN₃O 
• 1576239-82-1 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-phenylbutan-1-one 
• 313368-96-6 (6bR,10aS)-8-[3-(4-fluorophenoxy)propyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 
• 1576239-84-3 4-fluoro-N-[2-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)ethyl]benzamide 
• 1576239-87-6 (6bR,10aS)-8-[(3-(4-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl]-3-methyl-2,3,6b,7,8,9,10,10aoctahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 
• 313368-91-1 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-92-2 4-((6bS,10aR)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one 
• 313368-93-3 4-((6bR,10aS)-3-ethyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-94-4 4-((6bR,10aS)-3-isopropyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 

Relevant articles and documents

Preparation method of Lumateperone intermediate

The invention discloses a preparation method of a Lumateperone intermediate. The Lumateperone intermediate (6bR, 10aS)-2, 3, 6b, 9, 10, 10a-hexahydro-3-methyl-1H-pyridine[3', 4':4, 5] pyrrolo [1, 2, 3-de] quinoxaline-8 (7H) carboxylic acid ethyl ester is

SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF

The present disclosure relates to solid state forms of Lumateperone besylate, processes for preparation thereof and pharmaceutical compositions thereof.

ITI-007

A great deal has been achieved in the treatment of schizophrenia in recent decades, especially the treatment of the positive symptoms by targeting dopamine D2 receptors. But the disease has a range of other symptoms which gravely affect quality of life and which require other strategies or additional targets. Among the agents gradually filling the empty therapeutic space is ITI-007, which has an unusual mechanistic profile: it targets 5-HT2A and dopamine D2 receptors, but has a much higher affinity for the former receptors. This may allow the drug's effects to be modified by dose adjustments, with effects on sleep disturbances, depression and anxiety seen with lower doses and higher doses affecting the positive symptoms of schizophrenia through dopamine D2 receptor modulation. Higher doses can also inhibit serotonin transporters and produce glutamatergic modulation which could improve positive and negative symptoms, depressive symptoms and cognitive impairments. The findings of preclinical studies have supported this view of the drug, and a phase II study found effects on positive and negative symptoms with a safety profile distinct from atypical antipsychotics. Phase III investigation in schizophrenia has begun, and clinical investigation in insomnia and dementia is also under way.